Novanta Inc 8-K, filed Dec 1, 2025
Novanta Inc (NOVT)
About this 8-K
Novanta Inc filed this 8-K on December 1, 2025.
Items reported
- Item 7.01: Regulation FD disclosure
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in is charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
||
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure
Effective December 1, 2025, Novanta Inc. (the “Company”) appointed Alexander Manganiello as General Counsel and Corporate Secretary. In this role, Mr. Manganiello will lead the Company’s global legal, regulatory, corporate secretary, and trade compliance organizations. He brings to the Company 30 years of experience working with global, public companies across multiple industries. From 2019 until joining the Company, Mr. Manganiello was with Vertex Pharmaceuticals Incorporated (NYSE: VRTX), most recently serving as Vertex’s Vice President, Deputy General Counsel. From 2004 through 2019, Mr. Manganiello served in a variety of increasingly senior legal roles at Pfizer Inc. (NYSE: PFE). Prior to Pfizer, he practiced law within the corporate department of Ropes & Gray (Boston, MA). Mr. Manganiello holds an A.B., Biology from Harvard University and a J.D. from Suffolk Law School.
The information contained in this Item 7.01 is furnished under Item 7.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
Novanta Inc. |
|
|
|
|
|
Date: December 1, 2025 |
|
By: |
/s/ Robert J. Buckley |
|
|
|
Robert J. Buckley |
|
|
|
Chief Financial Officer |